GTC Biotherapeutics (fka GTCB)

[DewDiligence]

New multifaceted survey:

1: What is the probability of regulatory
approval of ATryn for DIC/sepsis in
any jurisdiction?

a) Less than 20%
b) 20-39%
c) 40-59%
d) 60-79%
e) 80% or more


2. What is the probability of FDA approval
of ATryn for hereditary deficiency?

a) Less than 20%
b) 20-39%
c) 40-59%
d) 60-79%
e) 80% or more


3. What is the probability of approval of
GTC/LFB transgenic FVIIa in any jurisdiction?

a) Less than 20%
b) 20-39%
c) 40-59%
d) 60-79%
e) 80% or more


4: Of the items listed below, the largest
component of GTC’s underlying value is:

a) The ATryn collaboration with Leo (HD and DIC)
b) The unpartnered ATryn program in the U.S.
c) The collaboration with LFB
d) The intellectual property
e) Everything else combined


5. My current position in GTCB is:

a) Long
b) Short
c) None

--
To vote, please go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=4135 .
and select survey #4.